Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome | Zendy

Investigators | Zendy; John H. Alexander | Zendy; Richard C. Becker | Zendy; Deepak L. Bhatt | Zendy; Frank Cools | Zendy; Filippo Crea | Zendy; Mikael Dellborg | Zendy; Keith A.A. Fox | Zendy; Shaun G Goodman | Zendy; Robert A Harrington | Zendy; Kurt Huber | Zendy; Steen Husted | Zendy; Basil S. Lewis | Zendy; José LópezSendón | Zendy; Puneet Mohan | Zendy; Gilles Montalescot | Zendy; Mikhail Ruda | Zendy; Witold Rużyłło | Zendy; Freek W.A. Verheugt | Zendy; Lars Wallentin | Zendy

Open Access

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome

Author(s) -

Investigators,

John H. Alexander,

Richard C. Becker,

Deepak L. Bhatt,

Frank Cools,

Filippo Crea,

Mikael Dellborg,

Keith A.A. Fox,

Shaun G Goodman,

Robert A Harrington,

Kurt Huber,

Steen Husted,

Basil S. Lewis,

José LópezSendón,

Puneet Mohan,

Gilles Montalescot,

Mikhail Ruda,

Witold Rużyłło,

Freek W.A. Verheugt,

Lars Wallentin

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.832139

Subject(s) - medicine , apixaban , acute coronary syndrome , hazard ratio , aspirin , myocardial infarction , placebo , stroke (engine) , clopidogrel , confidence interval , cardiology , rivaroxaban , atrial fibrillation , warfarin , mechanical engineering , alternative medicine , pathology , engineering

After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research